secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2026-03-04T23:59:59+00:00
Accession:  0001437749-26-006912
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell reports 2025 net operating income $1.6M; net loss narrows to $1.0M
---------------------------------------------------------------------------

- Product sales $27.6M, up 4.3% YoY; gross margin improved to 41.4% from 30%.
- Net loss $1.0M ($0.12/share) vs $2.2M ($0.26/share) in 2024.
- Net operating income $1.6M vs operating loss $1.6M in 2024.
- Non-recurring items: $2.7M Re-Tain write-down, $651K colostrum write-downs, $297K CEO transition costs, $427K insurance proceeds.
- Cash $3.8M, no debt draw; net working capital $13M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000143774926006912/0001437749-26-006912-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000143774926006912/iccc20260304_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-006912

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer